Clinical trials
Recurrent Ovarian Cancer clinical trials
Below are recruiting recurrent ovarian cancer clinical trials, each written for real people, not researchers. We’re tracking 226 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06843447RecruitingPhase 1/Phase 2
Study of raludotatug deruxtecan for ovarian cancer
This study tests a new drug called raludotatug deruxtecan for people with certain types of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. The drug is designed to target and kill cancer cells while sparing healthy tissue. It may be used alone or with other treatments, depending on the study group.
New Haven, ConnecticutAges 18 years+ - NCT04288999RecruitingPhase 3
Surgery plus chemo versus chemo-radiation then surgery for recurrent rectal cancer
This study compares two treatment plans for locally recurrent rectal cancer: (1) surgery plus chemo, or (2) chemo plus radiation first, then surgery, followed by chemo. It aims to see which approach works better in controlling the cancer and helping patients recover.
ChibaAges 20–80 - NCT03983226RecruitingPhase 2
Surgery plus niraparib for returning ovarian cancer
This trial tests whether adding niraparib (a pill treatment that targets cancer cell DNA repair) after surgery can help people with ovarian cancer that has come back. It focuses on “platinum-sensitive” cases and tries to remove all visible tumor when possible.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05255471RecruitingPhase 3
Olaparib after surgery for recurrent ovarian cancer
This trial tests whether olaparib (a pill cancer medicine) works better than standard platinum chemotherapy after a second surgery for recurrent ovarian cancer. It’s for people whose cancer returned after initial PARP-inhibitor (PARPi) maintenance and aims to see if treatment can control the cancer for longer with acceptable side effects.
NaplesAges 18 years+ - NCT03458221RecruitingPhase 2/Phase 3
Biology-guided test on recurrent ovarian cancer activity
This trial studies whether a targeted treatment, chosen based on tumor biology, can help people with recurrent ovarian cancer. You may be asked to give a tumor biopsy so researchers can analyze specific “signal” activity in your cancer.
Nijmegen, GelderlandAges 18 years+ - NCT04519151RecruitingPhase 2
Pembrolizumab plus lenvatinib for ovarian cancer that returned
This Phase 2 trial tests whether pembrolizumab plus lenvatinib can shrink ovarian cancer that has come back after platinum chemotherapy. You may be eligible if your cancer returned after a certain “time off” from prior treatment and you meet key health and safety requirements.
Ramat GanAges 18 years+ - NCT05444270Recruiting
Radiation and medicine for recurrent ovarian cancer
This trial studies a “salvage” (next-line) cancer treatment for recurrent epithelial ovarian cancer, with or without a focused type of radiation. It may help by shrinking or controlling limited spots of cancer that have come back after prior standard treatment.
SeoulAges 19 years+ - NCT05446545Recruiting
Blood and tissue tests to monitor ovarian cancer using tumor DNA
This study uses a custom lab test on blood (and tumor tissue) to track ovarian cancer returning and to see how well treatment is working. It may help your care team monitor changes over time, especially after certain surgeries.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06232122Recruiting
New PET scans to detect ovarian cancer recurrence
This study uses two types of PET/CT scans (68Ga-FAPI-46 and 18F-FDG) to look for any returning ovarian cancer. The goal is to find recurrence early so you and your doctor can plan the next steps.
Taoyuan CityAges 30–80 - NCT05753826RecruitingPhase 2
Study of two medicines for platinum-resistant ovarian cancer
This Phase 2 trial studies whether adding adebrelimab to fuzuloparib can help people with ovarian cancer that comes back quickly after platinum chemotherapy. It is aimed especially at tumors with a specific DNA-repair gene (HRR mutation).
FujianAges 18–70 - NCT06307249RecruitingPhase 1
Precision therapy for solid tumors targeting CDK4/6 and VEGF
This trial tests a combination of two targeted drugs for advanced solid tumors like colorectal, lung, breast, and genitourinary cancers. The goal is to see if blocking certain proteins and a long RNA molecule can slow tumor growth.
Tripoli, North LebanonAges 18 years+ - NCT05410717RecruitingPhase 1
CAR-NK cell therapy for certain solid tumors
This early-phase trial tests a lab-made immune cell treatment for advanced solid tumors that show specific targets (including Claudin 6, GPC3, Mesothelin, or AXL). It may help the immune system better recognize and kill tumor cells, but eligibility depends on test results and your overall health.
Guangzhou, GuangdongAges 18–75 - NCT06394492RecruitingPhase 3
Testing a new drug for platinum-resistant ovarian cancer
This study tests a new drug called SHR-A1921 for people with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07782164Recruiting
Irreversible electroporation for recurrent pelvic tumors
This study tests a new technique called irreversible electroporation (IRE) for treating pelvic tumors that have returned despite earlier treatment. IRE uses electrical pulses to destroy cancer cells without surgery, offering a potential option when other local treatments like surgery or radiation are not suitable.
Amsterdam, North HollandAges 18 years+ - NCT06014190RecruitingPhase 2
HS-20089 for ovarian and endometrial cancer
This trial tests a new medication (HS-20089) for people with ovarian or endometrial cancer that has come back or spread. It aims to see if the drug can shrink tumors or slow cancer growth.
Hefei, AnfeiAges 18 years+ - NCT07755436RecruitingPhase 1
Study of ARR-002 for advanced ovarian or endometrial cancer
This study tests an experimental drug called ARR-002 in people with advanced or metastatic ovarian, primary peritoneal, or fallopian tube cancer that has stopped responding to standard treatments. The goal is to see if it is safe and whether it shrinks tumors.
Orlando, FloridaAges 18 years+ - NCT07736937RecruitingPhase 1/Phase 2
Study of TUB-040 with Standard Drugs for Ovarian Cancer
This study tests a new medicine called TUB-040, given together with standard ovarian cancer drugs like carboplatin and bevacizumab. It is for women with ovarian cancer that has returned after responding to platinum-based chemotherapy and is growing again. The goal is to see if this combination can help control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT07718854RecruitingPhase 2
Study of two drugs for advanced ovarian clear cell cancer
This study tests two investigational drugs, alone or together, for advanced ovarian clear cell cancer that has not responded to usual treatments. The goal is to see if these drugs help shrink or control the cancer.
Boston, MassachusettsAges 18 years+ - NCT07714668RecruitingPhase 2
Combination therapy for recurrent ovarian cancer
This study tests a new combination treatment for ovarian cancer that has come back after earlier treatment. It aims to see if the combination can shrink tumors or slow the disease, and it may be an option for people whose cancer has become resistant to platinum-based chemotherapy.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04921527RecruitingPhase 3
Chiauranib with weekly paclitaxel for tough ovarian cancer
This Phase 3 trial tests whether chiauranib combined with weekly paclitaxel can shrink recurrent ovarian, fallopian tube, or primary peritoneal cancer that did not respond to platinum chemotherapy. It is designed for people who have limited treatment options after platinum-resistant or platinum-refractory disease.
Shanghai, ChinaAges 18–70 - NCT06660511RecruitingEarly Phase 1
Combination therapy for HER2-positive platinum-resistant ovarian cancer
This trial tests a combination of two drugs—Disitamab Vedotin and Anlotinib—for patients with ovarian cancer that has come back after platinum chemotherapy. It is designed for people whose tumors show a specific protein called HER2, and it aims to see if the combination is safe and effective.
Changsha, HunanAges 18 years+ - NCT07667192Recruiting
Re-treating gynecologic cancer with repeat radiation or ablation
This trial studies using additional radiation or tumor-destroying techniques for gynecologic cancer that has come back after previous radiation treatment. It helps doctors understand if this approach is safe and effective for women with recurrent disease.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT07651124Recruiting
Testing a cell therapy for recurrent ovarian cancer
This trial tests a treatment where doctors take immune cells from your tumor, grow more of them in the lab, and put them back into your body to fight the cancer. This approach, called TIL therapy, aims to strengthen your own immune system to target ovarian cancer that has come back.
Gyeonggi-do, Bundang-guAges 20 years+ - NCT07617753RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Recurrent Ovarian Cancer
This trial tests a new type of cell therapy using modified natural killer cells (CAR-NK cells) that are trained to attack ovarian cancer cells. It's designed for patients whose cancer has come back or stopped responding to previous treatments.
Shenzhen, GuangdongAges 18–75
Hear when a new Recurrent Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Recurrent Ovarian Cancer trials by city
Studies with a site in or near these metro areas.
Recurrent Ovarian Cancer trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for recurrent ovarian cancer?
- Yes. Clin2 currently lists 226 recruiting recurrent ovarian cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent ovarian cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.